Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
In a big move, India has opened up Covid-19 vaccinations for all adults. However, the country is beset by severe vaccine shortage and other challenges. Will increasing the demand base work?
The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
One of the issues with vaccine development is the enormous time required to produce one. The Covid-19 vaccine has shown the process can be expedited. But can the process be made even more faster?
RDIF has tied up with nearly a dozen contract manufacturers with idle capacity to produce some 1.5 billion doses of Sputnik V annually, more than what Serum and Bharat Biotech will jointly produce.
In the context of vaccination, effective communication should deliver clarity around who, when, where, and how much the vaccine will cost. And India's vaccine deployment can be a great case study.
The second phase of the Covid-19 vaccine, which is currently underway, requires the private sector's involvement more than ever before. And the sector is rising up to the challenge.
The Covid-19 pandemic has amplified the importance of cold-chain infrastructure, and Godrej Appliances’ medical refrigeration business is making the most of the opportunity.
As India starts the second phase of its Covid-19 vaccine deployment, the question on the viability of its supply chain network, and its cold storage capability, has become more pertinent than ever.
